TMDI - TMDI STOCK NEWS

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD) announced the immediate departure of Perry Genova, Senior Vice President of Research and Product Development, as it shifts focus from technology R&D to regulatory clearance and commercialization. Interim President Paul Cataford noted that the company's evolving needs necessitated this change. Titan Medical continues to develop the Enos™ robotic single access surgical system, which aims to enhance surgical procedures with ergonomic design for gynecologic indications. The company operates in Toronto and Chapel Hill, North Carolina.

Titan Medical Inc. (NASDAQ: TMDI; TSX: TMD) will present its Enos™ robotic surgical system at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami, Florida. Paul Cataford, the Interim President and CEO, along with CFO Stephen Lemieux, will lead the presentation on May 25 at 4:30 pm ET, available via webcast. The Enos system is designed for robotic single access surgery, enhancing surgeon dexterity with multi-articulating instruments aimed initially at gynecologic procedures. For more details, visit www.titanmedicalinc.com.

Titan Medical Inc. (NASDAQ: TMDI) has reported its financial results for Q1 2022, showing cash reserves of $30.1 million. The company is advancing towards its regulatory goals for the Enos robotic surgical system, with an IDE application submission planned for Q1 2023. R&D expenses rose to $9.4 million, aligned with product development efforts, while G&A expenses decreased to $2.5 million. Progress includes a purchase order with Medtronic for instrument evaluation, positive feedback from animal lab tests, and ongoing FDA communications to mitigate timeline risks.

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD) will hold its 2022 Annual and Special Meeting on June 8, 2022, at 4:00 p.m. ET, virtually. Shareholders of record by May 26, 2022, are entitled to vote on key agenda items including the presentation of audited financial statements for 2021, election of directors, and appointment of auditors. Proposed plans for amendment and renewal of share unit plans, as well as the adoption of an employee share purchase plan, will also be considered. Additional details can be found in the proxy materials.

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD) has received a purchase order worth $2.6 million from Medtronic plc (NYSE: MDT) for surgical instruments and cameras. This order aims to facilitate preclinical activities and assess Titan as a potential manufacturing partner for Medtronic. Interim President and CEO Paul Cataford expressed enthusiasm about this collaboration, noting Titan's expanding manufacturing capabilities in Chapel Hill. Titan is developing the Enos robotic surgical system, focusing on enhancing robotic-assisted surgery.

Titan Medical Inc. (TMDI) will release its Q1 2022 financial results before market open on May 12, 2022. The company will host an audio webcast at 8:30 a.m. ET featuring Interim President and CEO Paul Cataford and CFO Stephen Lemieux discussing financial outcomes and business developments. Titan Medical is focused on advancing robotic-assisted surgery through its Enos™ system, aimed initially at gynecologic applications. The company emphasizes innovation and improved surgical experiences with enhanced dexterity and functionality.

Titan Medical Inc. (NASDAQ: TMDI), a company specializing in robotic-assisted surgery, will present its Enos™ system at the Bloom Burton & Co. Healthcare Investor Conference on May 2-3, 2022, in Toronto. Interim President and CEO, Paul Cataford, along with CFO Stephen Lemieux, will provide insights and engage in investor meetings. The presentation is scheduled for May 2 at 3:30 PM ET and will be available via live webcast on the company's website. Titan is focused on enhancing surgical innovation and initially targeting gynecologic surgical applications.

Titan Medical Inc. (NASDAQ: TMDI) reported financial results for Q4 and the year ending December 31, 2021. Key achievements include receiving a net payment of $8.3 million from Medtronic and retiring a $2.3 million loan. The company has expanded its patent portfolio to over 200 and completed its Chapel Hill facility buildout. R&D expenses surged to $37.9 million for the year, reflecting ongoing developments for the Enos system. Cash and equivalents increased to $32.3 million from $25.5 million in 2020.

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD) will release its year-end 2021 financial results on March 24, 2022, before market opening. An investor audio webcast will be held at 8:30 a.m. ET to discuss these results and key business highlights. The company is focused on single access robotic-assisted surgery, developing the Enos™ surgical system aimed at enhancing surgical performance. The webcast will be accessible on the company's website and will include speakers Paul Cataford and Stephen Lemieux.